When stratified, the median survival was 6.01 (95% CI: 2.75-NA) years for patients who had immunotherapy for their NSCLC and an ALK or EGFR mutation that required targeted therapy in the form of TKIs and mAbs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.